{
    "hands_on_practices": [
        {
            "introduction": "Effective management of angioedema begins with a fundamental clinical skill: differentiating the underlying pathophysiological pathway directly from the patient's presentation. This initial assessment determines all subsequent diagnostic and therapeutic steps. This exercise  challenges you to analyze a classic clinical vignette and deduce whether mast-cell or bradykinin-mediated mechanisms are responsible, using key features like the presence or absence of urticaria, specific triggers, and family history.",
            "id": "4411751",
            "problem": "A patient presents to a dermatology and venereology clinic with a history of episodic facial and lip swelling. The patient is a $29$-year-old woman with recurrent, nonpitting edema of the perioral and periorbital regions. Episodes last $48$ to $72$ hours and often follow periods of psychological stress or minor procedures such as dental cleanings. She denies pruritus and has never had urticarial wheals. One prior episode was accompanied by cramping abdominal pain and vomiting. During a previous attack, she received an oral histamine type $1$ receptor blocker and systemic glucocorticoids without improvement. There is a family history of similar swelling in her father in his $30$ s. She takes no medications known to affect the kallikrein-kinin pathway, including no Angiotensin-Converting Enzyme (ACE) inhibitor. Examination today shows mild, nonerythematous lower lip swelling; there is no wheal-and-flare reaction on adjacent skin and no respiratory distress.\n\nUsing core definitions of effector pathways in angioedema—namely, (i) mast cell degranulation with histamine release acting on histamine type $1$ receptors typically producing pruritic wheals and responding to antihistamines, and (ii) bradykinin generation via the contact system regulated by C1 esterase inhibitor (C1-INH) acting on bradykinin B2 receptors to increase vascular permeability without urticaria—determine which pathway is most likely implicated in this patient’s pathophysiology.\n\nSelect the single best answer.\n\nA. Mast cell activation with Immunoglobulin E (IgE)-mediated histamine release\n\nB. Bradykinin-mediated angioedema due to contact system dysregulation\n\nC. Generalized capillary leak from hypoalbuminemia causing dependent edema\n\nD. Leukotriene excess from aspirin-exacerbated respiratory disease causing facial angioedema\n\nE. Type IV T-cell–mediated delayed hypersensitivity reaction causing swelling",
            "solution": "The problem statement is assessed to be valid. It is scientifically grounded, well-posed, objective, and internally consistent. It provides a classic clinical vignette that is sufficient for determining the most likely underlying pathophysiological pathway from the presented options.\n\nThe task is to determine the most likely effector pathway for a $29$-year-old woman presenting with recurrent, nonpitting angioedema. The problem statement provides two core definitions for the major pathways of angioedema:\n(i) A mast cell-driven, histamine-mediated pathway, characteristically associated with urticaria and pruritus, and responsive to antihistamines.\n(ii) A bradykinin-mediated pathway, resulting from contact system activation, which is regulated by C1 esterase inhibitor (C1-INH). This pathway is characterized by angioedema without urticaria and does not respond to antihistamines.\n\nWe will analyze the patient's clinical features in the context of these two pathways.\n\n1.  **Clinical Symptoms**: The patient experiences recurrent, nonpitting edema of the perioral and periorbital regions. Crucially, she **denies pruritus** and has **never had urticarial wheals**. This clinical picture directly contradicts the typical presentation of histamine-mediated angioedema (Pathway i), which is defined by pruritic wheals, and aligns perfectly with the description of bradykinin-mediated angioedema (Pathway ii), which causes swelling without urticaria.\n\n2.  **Treatment Response**: The patient received an oral histamine type $1$ receptor blocker and systemic glucocorticoids during a previous attack **without improvement**. The lack of response to antihistamines is a cardinal feature that points away from histamine as the primary mediator and strongly supports a non-histaminergic mechanism, such as bradykinin. Glucocorticoids are also generally ineffective for bradykinin-mediated attacks.\n\n3.  **Associated Symptoms**: The patient experienced an episode accompanied by **cramping abdominal pain and vomiting**. Edema of the bowel wall is a well-known and common manifestation of bradykinin-mediated angioedema, particularly hereditary angioedema (HAE), leading to severe gastrointestinal symptoms. While possible, severe GI involvement is less characteristic of typical allergic angioedema.\n\n4.  **Triggers**: The episodes are noted to follow periods of **psychological stress** or **minor procedures** such as dental cleanings. These are classic triggers for attacks of HAE, a primary cause of bradykinin-mediated angioedema. Trauma, even minor, can activate the contact system (Hageman factor), leading to a cascade of bradykinin generation in individuals with deficient C1-INH.\n\n5.  **Family History**: There is a family history of **similar swelling in her father**. This suggests a genetic, likely autosomal dominant, inheritance pattern. HAE types I and II are inherited in an autosomal dominant fashion and are the most common causes of recurrent, bradykinin-mediated angioedema that is not drug-induced. The absence of a history of ACE inhibitor use rules out the most common cause of acquired bradykinin-mediated angioedema.\n\nIn summary, every key feature of the patient’s presentation—absence of urticaria and pruritus, lack of response to antihistamines and glucocorticoids, gastrointestinal involvement, specific triggers, and a positive family history—points to a dysregulation of the kallikrein-kinin system leading to excess bradykinin.\n\nNow, we evaluate each option:\n\n**A. Mast cell activation with Immunoglobulin E (IgE)-mediated histamine release**\nThis option describes the pathophysiology of Type I hypersensitivity, corresponding to Pathway (i). This mechanism results in histamine release, which classically produces pruritic urticaria (wheals) and angioedema that is responsive to antihistamines. The patient's clinical presentation is antithetical to this description, as she lacks pruritus, urticaria, and a response to antihistamines.\n**Verdict:** Incorrect.\n\n**B. Bradykinin-mediated angioedema due to contact system dysregulation**\nThis option describes Pathway (ii). The pathophysiology involves excessive production of bradykinin, a potent vasodilator that increases vascular permeability, leading to non-pruritic, non-urticarial angioedema. The lack of C1-INH, a key regulator of the contact system, is the underlying defect in HAE. This mechanism precisely explains all aspects of the patient's presentation: the type of swelling, the triggers, the associated gastrointestinal symptoms, the lack of response to standard allergy treatments, and the suggestive family history.\n**Verdict:** Correct.\n\n**C. Generalized capillary leak from hypoalbuminemia causing dependent edema**\nHypoalbuminemia leads to a decrease in plasma oncotic pressure, resulting in a generalized, chronic, and pitting edema that is typically dependent (i.e., accumulates in the lowest parts of the body, such as the ankles). The patient has episodic, nonpitting edema localized to the face and lips, which is inconsistent with edema from low albumin.\n**Verdict:** Incorrect.\n\n**D. Leukotriene excess from aspirin-exacerbated respiratory disease causing facial angioedema**\nAspirin-exacerbated respiratory disease (AERD) is a specific clinical syndrome involving asthma, nasal polyposis, and hypersensitivity reactions to nonsteroidal anti-inflammatory drugs (NSAIDs). While angioedema can be a feature, the patient's history lacks any mention of asthma, nasal polyps, or NSAID triggers. Furthermore, the prominent family history and GI symptoms are much more characteristic of HAE.\n**Verdict:** Incorrect.\n\n**E. Type IV T-cell–mediated delayed hypersensitivity reaction causing swelling**\nType IV hypersensitivity reactions, such as contact dermatitis, are cell-mediated and typically develop over $24$ to $72$ hours after exposure to an antigen. They usually present as indurated, erythematous lesions. This mechanism does not fit the patient’s presentation of recurrent, profound, non-erythematous vasogenic edema with acute gastrointestinal symptoms and an autosomal dominant inheritance pattern.\n**Verdict:** Incorrect.",
            "answer": "$$\\boxed{B}$$"
        },
        {
            "introduction": "Once a bradykinin-mediated pathway is suspected, particularly in an acute setting, treatment decisions become critical and diverge significantly from standard allergy protocols. Understanding the specific molecular targets of different medications is essential to avoid administering ineffective therapies and delaying appropriate care. This practice  simulates an emergency scenario, requiring you to reason from first principles of pharmacology and pathophysiology to justify the decision to administer or withhold common treatments like antihistamines and corticosteroids.",
            "id": "4411843",
            "problem": "A $47$-year-old patient presents to the emergency department with isolated swelling of the lips and tongue that began insidiously $10$ hours ago. The patient reports a non-itchy, pressure-like discomfort without wheals or urticaria, and denies flushing, bronchospasm, or syncope. There is no response after appropriately dosed intramuscular epinephrine and airway-positioning maneuvers. Vital signs are stable. The patient is taking an angiotensin-converting enzyme inhibitor (ACEI) for hypertension. You must decide whether to administer corticosteroids and antihistamines at this point.\n\nUse the following foundational principles to reason your decision from first principles:\n- Immunoglobulin E (IgE)-mediated immediate hypersensitivity involves antigen cross-linking of mast cell surface IgE, triggering degranulation and rapid release of histamine and tryptase, which signal via histamine receptor $H1$ and $H2$ to increase vascular permeability and cause pruritus and urticaria.\n- Bradykinin-mediated angioedema arises from excessive generation or reduced degradation of bradykinin in the kallikrein-kinin pathway, often due to C1 esterase inhibitor (C1-INH) deficiency or ACEI-induced impaired bradykinin degradation. Bradykinin signals primarily via bradykinin receptor B2 on endothelium to increase nitric oxide and vascular permeability, typically without pruritus or urticaria, with a slower onset and longer duration.\n- Epinephrine, antihistamines, and corticosteroids each have mediator-specific pharmacodynamic targets: epinephrine via adrenergic receptors to counter mast cell-mediated vasodilation and permeability; antihistamines by antagonizing histamine receptors; corticosteroids by gene transcription modulation that suppresses late-phase inflammatory responses but do not directly inhibit active bradykinin signaling.\n\nWhich option best justifies whether to administer or withhold corticosteroids and antihistamines now?\n\nA. Administer both antihistamines and corticosteroids immediately because they directly inhibit bradykinin generation in the kallikrein-kinin cascade and should reverse symptoms within minutes.\n\nB. Withhold antihistamines and corticosteroids because the clinical picture and epinephrine non-response indicate bradykinin-mediated angioedema, in which histamine-targeted and steroid therapies lack acute efficacy; instead prioritize bradykinin-directed therapy such as C1-INH concentrate, a bradykinin B2 receptor antagonist, or a plasma kallikrein inhibitor, along with airway protection.\n\nC. Administer antihistamines only because both histamine and bradykinin converge on endothelial nitric oxide production; blocking histamine should reduce at least half of the edema even if bradykinin is the main driver.\n\nD. Administer corticosteroids only because they rapidly upregulate hepatic C1-INH synthesis and will shorten the attack course within $1$ to $2$ hours.\n\nE. Administer both empirically because a normal or unavailable serum tryptase cannot exclude mast cell activation early; the low risk of these drugs justifies their use while arranging definitive therapy.\n\nSelect the single best option.",
            "solution": "The problem statement is evaluated as valid. It presents a scientifically grounded, well-posed, and objective clinical scenario that can be analyzed using the provided foundational principles. The data are internally consistent and sufficient to derive a unique, logical solution.\n\nThe core of this problem requires a differential diagnosis of angioedema based on the patient's clinical presentation and medication history, followed by a decision on therapy based on pathophysiological and pharmacological principles.\n\n**Analysis of the Clinical Presentation**\n\nThe patient is a $47$-year-old on an angiotensin-converting enzyme inhibitor (ACEI). The key features of the presentation are:\n1.  **Symptomatology**: Isolated swelling of the lips and tongue, described as a non-itchy, pressure-like sensation, explicitly without wheals or urticaria.\n2.  **Chronology**: An insidious onset over $10$ hours.\n3.  **Treatment Response**: No response to intramuscular epinephrine.\n\nThese features must be interpreted using the provided foundational principles.\n\n- The first principle describes Immunoglobulin E (IgE)-mediated angioedema, which is characterized by the rapid release of histamine, leading to pruritus (itching) and urticaria (wheals). The patient's presentation—non-itchy, no urticaria, and slow onset—is inconsistent with an IgE-mediated process.\n\n- The second principle describes bradykinin-mediated angioedema. This can be caused by impaired bradykinin degradation due to ACEIs. Bradykinin is a peptide that is normally degraded by several enzymes, including angiotensin-converting enzyme (which is also known as kininase II). Inhibition of this enzyme by an ACEI can lead to accumulation of bradykinin. The principle states that bradykinin-mediated angioedema typically occurs without pruritus or urticaria and has a slower onset and longer duration. This profile perfectly matches the patient's presentation.\n\n- The third principle discusses the mechanisms of relevant drugs. Epinephrine counters mast cell-mediated effects. The patient's lack of response to epinephrine is a critical finding that further argues against a mast cell-mediated (and therefore histamine-mediated) process and strongly supports a bradykinin-mediated etiology.\n\nBased on this analysis, the patient is experiencing bradykinin-mediated angioedema, very likely induced by the ACEI. The therapeutic decision must be based on this diagnosis. The question is whether to administer corticosteroids and antihistamines.\n\n- **Antihistamines**: According to the principles, antihistamines work by blocking histamine receptors (H1 and H2). Since the pathophysiology is driven by bradykinin, not histamine, antihistamines will have no significant effect. Their target is not the primary mediator of the pathology.\n\n- **Corticosteroids**: The principles state that corticosteroids work by modulating gene transcription to suppress late-phase inflammation and, crucially, \"do not directly inhibit active bradykinin signaling.\" Their onset of action is inherently slow (hours to days), making them ineffective for an acute, life-threatening condition like angioedema of the tongue. Furthermore, their mechanism is not directed at the bradykinin pathway.\n\nTherefore, from first principles, both antihistamines and corticosteroids are expected to be ineffective in the acute management of this patient's bradykinin-mediated angioedema. The appropriate course of action is to withhold these drugs and pursue therapies that directly target the bradykinin cascade.\n\n**Evaluation of the Options**\n\n**A. Administer both antihistamines and corticosteroids immediately because they directly inhibit bradykinin generation in the kallikrein-kinin cascade and should reverse symptoms within minutes.**\nThis statement is factually incorrect. The provided principles clearly state that antihistamines antagonize histamine receptors and corticosteroids modulate gene transcription. Neither agent directly inhibits bradykinin generation. The claim of symptom reversal within minutes is also false, especially for corticosteroids.\n**Verdict: Incorrect.**\n\n**B. Withhold antihistamines and corticosteroids because the clinical picture and epinephrine non-response indicate bradykinin-mediated angioedema, in which histamine-targeted and steroid therapies lack acute efficacy; instead prioritize bradykinin-directed therapy such as C1-INH concentrate, a bradykinin B2 receptor antagonist, or a plasma kallikrein inhibitor, along with airway protection.**\nThis option correctly synthesizes the clinical evidence: the characteristic symptoms (`clinical picture`) and lack of response to epinephrine point to bradykinin-mediated angioedema. It correctly concludes from the principles that therapies targeting histamine and general inflammation (corticosteroids) lack acute efficacy. It correctly identifies the appropriate management strategy, which is to withhold ineffective drugs and prioritize therapies that target the bradykinin pathway (such as C1 esterase inhibitor (C1-INH) concentrate, icatibant (a bradykinin B2 receptor antagonist), or ecallantide (a plasma kallikrein inhibitor)) and ensure airway safety. This reasoning is a perfect application of the provided principles to the clinical scenario.\n**Verdict: Correct.**\n\n**C. Administer antihistamines only because both histamine and bradykinin converge on endothelial nitric oxide production; blocking histamine should reduce at least half of the edema even if bradykinin is the main driver.**\nThis option makes an unsupported and clinically incorrect claim. The principle states bradykinin increases nitric oxide, but does not specify this for histamine. Even if there were some minor pathway convergence, the assertion that blocking a non-primary mediator would reduce the effect by \"at least half\" is a quantitative claim without any basis in the provided principles or in established pharmacology. In bradykinin-driven angioedema, the contribution from histamine is negligible, so blocking it would be futile.\n**Verdict: Incorrect.**\n\n**D. Administer corticosteroids only because they rapidly upregulate hepatic C1-INH synthesis and will shorten the attack course within $1$ to $2$ hours.**\nThis statement contains multiple errors. First, corticosteroids do not act \"rapidly\" in this context; their genomic mechanism is slow. Second, while certain hormonal agents (anabolic androgens) are used for long-term prophylaxis in hereditary angioedema to increase C1-INH levels, corticosteroids are not the primary agents for this, and such an effect is completely irrelevant for reversing an acute attack, especially one caused by ACEI-induced bradykinin excess rather than C1-INH deficiency. The principles state corticosteroids do not directly inhibit active bradykinin signaling, which contradicts the premise of this option.\n**Verdict: Incorrect.**\n\n**E. Administer both empirically because a normal or unavailable serum tryptase cannot exclude mast cell activation early; the low risk of these drugs justifies their use while arranging definitive therapy.**\nThis option advocates an undifferentiated, empiric approach that contradicts the strong evidence presented. The clinical picture (no pruritus, no urticaria, slow onset) combined with the definitive finding of epinephrine non-response makes a mast-cell-driven process exceptionally unlikely. Reasoning from first principles, as the prompt requires, leads to a specific diagnosis and targeted therapy. Administering ineffective drugs is poor medical practice, can provide a false sense of security, and may delay the implementation of effective, potentially life-saving treatments. The problem is structured to reward precise, principle-based reasoning, not empiricism in the face of strong counter-evidence.\n**Verdict: Incorrect.**",
            "answer": "$$\\boxed{B}$$"
        },
        {
            "introduction": "Moving beyond individual case analysis, the final step in mastering angioedema is to develop a systematic and robust diagnostic strategy. A well-designed workflow ensures that clinical and laboratory data are collected and interpreted in a logical sequence, leading to an accurate and timely diagnosis while minimizing the risk of errors. This capstone exercise  asks you to evaluate several proposed diagnostic algorithms and select the one that most coherently integrates clinical triage, response to initial therapy, and the appropriate use of biomarkers like serum tryptase and complement components.",
            "id": "4411844",
            "problem": "A tertiary emergency department seeks to implement a decision workflow that separates mast cell–mediated allergic angioedema from bradykinin–mediated Hereditary Angioedema (HAE) at first presentation, and guides confirmatory testing. The clinical team agrees that the workflow must be grounded in core pathophysiologic distinctions and must explicitly incorporate three decision axes: timing of symptom onset and peak, clinical response to intramuscular epinephrine, and laboratory biomarkers available in acute and convalescent windows. The available assays are serum tryptase (acute sample at $1$–$4$ hours after onset and a baseline sample at $24$–$48$ hours), complement component C4, and C1 esterase inhibitor (C1-INH) antigenic level and functional activity. The clinical features that can be reliably collected include presence or absence of urticaria and pruritus, and the time from trigger to onset and peak swelling.\n\nFrom first principles, mast cell–mediated allergic angioedema is characterized by rapid mediator release and is expected to respond to catecholamines and antihistamines, while bradykinin–mediated HAE is characterized by excessive kallikrein–kinin activity due to C1-INH dysfunction, slower onset, absence of urticaria, and poor response to epinephrine. Serum tryptase is a mast cell granule protease and may rise transiently after mast cell activation; complement C4 is expected to be low in HAE due to classical pathway consumption, whereas C1-INH evaluation distinguishes quantitative deficiency from functional defects. Angiotensin-Converting Enzyme (ACE) inhibitor–induced angioedema is bradykinin mediated but is not the focus unless the workflow’s bradykinin branch appropriately captures it without conflating hereditary and acquired etiologies.\n\nWhich proposed workflow most robustly separates allergic angioedema from HAE and aligns with these mechanistic bases, while using timing, epinephrine response, and the specified biomarkers in a scientifically coherent sequence?\n\nA. Begin with clinical timing and cutaneous phenotype. If onset to peak is $< 60$ minutes with urticaria/pruritus and there is clear improvement after intramuscular epinephrine, classify provisionally as mast cell–mediated. Obtain an acute serum tryptase at $1$–$4$ hours and a baseline at $24$–$48$ hours; confirm mast cell activation by comparing post-event to baseline using validated relative-change criteria. If onset is $> 3$ hours without urticaria/pruritus and there is poor response to epinephrine, obtain C4 promptly; if C4 is low, proceed to C1-INH antigenic and functional assays (preferably between attacks) to confirm HAE and subtype (Type I: low antigen and function; Type II: normal antigen but low function). Consider C1q subsequently only if clinical features suggest acquired angioedema.\n\nB. Start with serum tryptase using a fixed absolute cutoff. If acute tryptase is $> 11$ ng/mL, diagnose allergic angioedema regardless of timing or epinephrine response; if $\\leq 11$ ng/mL, diagnose HAE and confirm with C3 level. No baseline tryptase is required; C4 and C1-INH testing are unnecessary.\n\nC. Use response to intramuscular epinephrine as the decisive discriminator. If swelling improves within $30$ minutes, diagnose allergic angioedema; if not, diagnose HAE. Laboratory testing is reserved for later research and does not affect acute classification.\n\nD. Start with complement testing prioritizing C3 and total Immunoglobulin E (IgE). If C3 is low and total IgE is high, diagnose allergic angioedema; if C3 is normal and total IgE is low, diagnose HAE. Serum tryptase and C4 are not required because they are nonspecific and time consuming.\n\nE. Begin with medication review for ACE inhibitors. If an ACE inhibitor is present, classify as HAE because it is bradykinin mediated; if not, classify as allergic. Confirm with a single C4 measurement; if C4 is normal, the diagnosis of allergic angioedema is secure and C1-INH testing is unnecessary.",
            "solution": "The problem statement is assessed to be valid. It presents a scientifically grounded, well-posed, objective scenario that requires the evaluation of several proposed diagnostic workflows for differentiating allergic angioedema from Hereditary Angioedema (HAE). The goal is to select the workflow that is most coherent, sequential, and based on established pathophysiological principles.\n\nA robust workflow should start with clinical triage, incorporate response to initial therapy, and guide the use of specific biomarkers in a logical sequence. Let's analyze the proposed workflows against these criteria.\n\n**A. Begin with clinical timing and cutaneous phenotype...**\nThis workflow follows a perfect logical sequence.\n1.  **Clinical Triage**: It correctly uses the presence/absence of urticaria/pruritus and the speed of onset to form a provisional diagnosis (allergic vs. bradykinin-mediated).\n2.  **Therapeutic Response**: It incorporates the response to epinephrine as a key decision point, which is a critical real-world differentiator.\n3.  **Biomarker Confirmation**: It uses the correct biomarkers for each suspected pathway. For suspected allergic angioedema, it correctly specifies measuring both acute and baseline tryptase to look for a relative change, which is the current best practice. For suspected HAE, it correctly specifies a C4 screen followed by confirmatory C1-INH antigenic and functional assays.\n4.  **Sophistication**: It correctly defines HAE subtypes and appropriately places C1q testing as a subsequent step for suspected acquired angioedema.\n**Verdict: Correct.** This workflow is scientifically sound, logically sequenced, and clinically practical.\n\n**B. Start with serum tryptase using a fixed absolute cutoff...**\nThis workflow is flawed.\n1.  Using a fixed absolute cutoff for tryptase is not recommended, as baseline levels vary. The change from baseline is the key diagnostic indicator.\n2.  It incorrectly uses the C3 level to confirm HAE. The relevant complement component that is consumed in HAE is C4, not C3.\n3.  It dismisses the need for C4 and C1-INH testing, which are essential for diagnosing HAE.\n**Verdict: Incorrect.**\n\n**C. Use response to intramuscular epinephrine as the decisive discriminator...**\nThis workflow is overly simplistic and potentially unsafe.\n1.  While response to epinephrine is a strong indicator, it should not be the sole criterion. Some severe allergic reactions may be refractory to initial doses, and response can be difficult to assess objectively.\n2.  Dismissing laboratory testing is a major error. A definitive diagnosis is required for proper long-term management, patient education, and prescription of life-saving on-demand therapies for HAE.\n**Verdict: Incorrect.**\n\n**D. Start with complement testing prioritizing C3 and total Immunoglobulin E (IgE)...**\nThis workflow uses incorrect and non-specific markers.\n1.  As in option B, C3 is not the correct complement marker for HAE screening.\n2.  Total IgE is a poor screening test for acute allergic reactions, as levels can be high in non-allergic individuals and normal in allergic ones.\n3.  It wrongly dismisses tryptase and C4 as \"nonspecific and time consuming,\" when they are in fact the key, specific markers.\n**Verdict: Incorrect.**\n\n**E. Begin with medication review for ACE inhibitors...**\nThis workflow contains critical diagnostic errors.\n1.  It incorrectly conflates ACE inhibitor-induced angioedema (an acquired form) with HAE (a hereditary form). While both are bradykinin-mediated, their etiology and long-term management are different.\n2.  It makes a dangerous oversimplification by classifying all non-ACE inhibitor cases as allergic, ignoring HAE entirely.\n3.  It misuses the C4 test, claiming a normal C4 \"secures\" a diagnosis of allergic angioedema, which is false. A normal C4 is expected in many conditions, including HAE with normal C1-INH.\n**Verdict: Incorrect.**\n\nTherefore, workflow A is the only one that represents a robust, evidence-based diagnostic algorithm.",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}